$3.57 Billion is the total value of Perceptive Advisors's 137 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 118.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FOLD | Buy | AMICUS THERAPEUTICS INC | $301,167,000 | +17.0% | 20,024,424 | +11.9% | 8.44% | -1.1% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $240,971,000 | +25.3% | 4,989,066 | +2.0% | 6.75% | +5.8% |
| LJPC | Buy | LA JOLLA PHARMACEUTICAL CO | $128,459,000 | +17.8% | 4,313,611 | +27.3% | 3.60% | -0.5% |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $104,141,000 | +172.6% | 6,162,202 | +29.0% | 2.92% | +130.2% |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $97,355,000 | – | 873,450 | +100.0% | 2.73% | – |
| ABMD | Buy | ABIOMED INC | $96,739,000 | +140.1% | 332,449 | +54.6% | 2.71% | +102.8% |
| DOVA | Buy | DOVA PHARMACEUTICALS INC | $75,420,000 | +44.8% | 2,780,977 | +53.7% | 2.11% | +22.3% |
| CORI | Buy | CORIUM INTERNATIONAL INC | $72,916,000 | +29.8% | 6,357,133 | +8.7% | 2.04% | +9.6% |
| RTRX | Buy | RETROPHIN INC | $71,839,000 | +27.6% | 3,212,871 | +20.2% | 2.01% | +7.8% |
| BHVN | Buy | BIOHAVEN PHARMACEUTICAL HLDG CO L | $71,224,000 | +911.0% | 2,927,449 | +1021.1% | 2.00% | +752.6% |
| ASND | New | ASCENDIS PHARMA A Ssponsored adr | $64,265,000 | – | 982,647 | +100.0% | 1.80% | – |
| MNLO | New | MENLO THERAPEUTICS INC | $60,089,000 | – | 1,598,958 | +100.0% | 1.68% | – |
| ALBO | Buy | ALBIREO PHARMA INC | $55,510,000 | +64.3% | 1,704,330 | +29.1% | 1.56% | +38.8% |
| DBVT | Buy | DBV TECHNOLOGIES S Asponsored adr | $48,296,000 | +100.6% | 2,093,498 | +113.9% | 1.35% | +69.5% |
| MMSI | Buy | MERIT MED SYS INC | $47,391,000 | +25.5% | 1,045,013 | +19.6% | 1.33% | +6.0% |
| MYOK | Buy | MYOKARDIA INC | $40,732,000 | +36.1% | 834,679 | +17.4% | 1.14% | +15.0% |
| XNCR | Buy | XENCOR INC | $39,516,000 | +37.3% | 1,318,095 | +0.4% | 1.11% | +16.0% |
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $33,745,000 | +36.6% | 2,802,821 | +4.4% | 0.94% | +15.4% |
| QURE | Buy | UNIQURE NV | $32,774,000 | +59.6% | 1,394,628 | +33.1% | 0.92% | +35.0% |
| New | SOLID BIOSCIENCES INC | $29,454,000 | – | 3,927,222 | +100.0% | 0.82% | – | |
| VRTX | Buy | VERTEX PHARMACEUTICALS INC | $24,756,000 | +19.2% | 151,898 | +9.6% | 0.69% | +0.6% |
| NEPT | Buy | NEPTUNE TECHNOLOGIES BIORESO | $24,092,000 | +21.9% | 8,574,015 | +2.4% | 0.68% | +3.1% |
| AKBA | Buy | AKEBIA THERAPEUTICS INC | $23,467,000 | -20.6% | 2,462,400 | +23.9% | 0.66% | -33.0% |
| TDOC | New | TELADOC INC | $20,956,000 | – | 520,000 | +100.0% | 0.59% | – |
| AGIO | New | AGIO PHARMACEUTICALS INC | $20,445,000 | – | 250,000 | +100.0% | 0.57% | – |
| ABLX | Buy | ABLYNX NVsponsored adr | $20,187,000 | +223.1% | 370,000 | +48.0% | 0.56% | +172.9% |
| ECYT | Buy | ENDOCYTE INC | $20,013,000 | +222.1% | 2,201,700 | +51.7% | 0.56% | +172.3% |
| RVNC | Buy | REVANCE THERAPEUTICS INC | $19,064,000 | +33.3% | 618,957 | +54.7% | 0.53% | +12.7% |
| ADMS | New | ADAMAS PHARMACEUTICALS INC | $15,057,000 | – | 630,000 | +100.0% | 0.42% | – |
| PTLA | New | PORTOLA PHARMACEUTICALS INC | $14,370,000 | – | 440,000 | +100.0% | 0.40% | – |
| ABEO | Buy | ABEONA THERAPEUTICS INC | $14,180,000 | +1398.9% | 998,162 | +1573.0% | 0.40% | +1180.6% |
| MOTS | New | MOTUS GI HLDGS INC | $12,591,000 | – | 2,810,542 | +100.0% | 0.35% | – |
| AGRX | Buy | AGILE THERAPEUTICS INC | $9,072,000 | -0.2% | 3,530,000 | +4.4% | 0.25% | -15.6% |
| SYBX | Buy | SYNLOGIC INC | $8,844,000 | +32.8% | 942,852 | +37.4% | 0.25% | +12.2% |
| PTCT | New | PTC THERAPEUTICS INC | $8,118,000 | – | 300,000 | +100.0% | 0.23% | – |
| CLSD | Buy | CLEARSIDE BIOMEDICAL INC | $7,681,000 | +76.9% | 715,181 | +15.3% | 0.22% | +49.3% |
| INCY | New | INCYTE CORPcall | $6,946,000 | – | 1,510,000 | +100.0% | 0.20% | – |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $6,793,000 | +809.4% | 171,978 | +682.5% | 0.19% | +660.0% |
| ACAD | New | ACADIA PHARMACEUTICALS INC | $6,179,000 | – | 275,000 | +100.0% | 0.17% | – |
| HSGX | Buy | HISTOGENICS CORP | $6,059,000 | +66.3% | 2,203,277 | +23.9% | 0.17% | +40.5% |
| BIIB | New | BIOGEN INC | $5,476,000 | – | 20,000 | +100.0% | 0.15% | – |
| NVTRQ | New | NUVECTRA CORP | $5,007,000 | – | 384,600 | +100.0% | 0.14% | – |
| ATNX | New | ATHENEX INC | $3,232,000 | – | 190,000 | +100.0% | 0.09% | – |
| ARWR | New | ARROWHEAD PHARMACEUTICALS INC | $2,635,000 | – | 365,445 | +100.0% | 0.07% | – |
| ADXS | New | ADVAXIS INC | $2,535,000 | – | 1,500,000 | +100.0% | 0.07% | – |
| AKCA | New | AKCEA THERAPEUTICS INC | $2,488,000 | – | 97,144 | +100.0% | 0.07% | – |
| INCY | New | INCYTE CORPput | $2,230,000 | – | 100,000 | +100.0% | 0.06% | – |
| MCK | New | MCKESSON CORP | $2,113,000 | – | 15,000 | +100.0% | 0.06% | – |
| PBYI | Buy | PUMA BIOTECHNOLOGY INCcall | $1,610,000 | +2827.3% | 200,000 | +100.0% | 0.04% | +2150.0% |
| XBI | Buy | SPDR SERIES TRUSTput | $1,548,000 | +167.4% | 900,000 | +50.0% | 0.04% | +126.3% |
| ITCI | New | INTRA CELLULAR THERAPIES INC | $1,474,000 | – | 70,000 | +100.0% | 0.04% | – |
| CBIO | New | CATALYST BIOSCIENCES IINC | $1,419,000 | – | 55,000 | +100.0% | 0.04% | – |
| PGNX | Buy | PROGENICS PHARMACEUTICALS IN | $1,212,000 | +229.3% | 162,500 | +162.7% | 0.03% | +183.3% |
| VIVE | New | VIVEVE MED INC | $1,226,000 | – | 334,894 | +100.0% | 0.03% | – |
| DVAX | New | DYNAVAX TECHNOLOGIES CORP | $1,106,000 | – | 55,713 | +100.0% | 0.03% | – |
| ENTA | New | ENANTA PHARMACEUTICALS INC | $739,000 | – | 9,132 | +100.0% | 0.02% | – |
| ARRY | New | ARRAY BIOPHARMA INC | $655,000 | – | 40,133 | +100.0% | 0.02% | – |
| NKTR | New | NEKTAR THERAPEUTICS | $644,000 | – | 6,057 | +100.0% | 0.02% | – |
| VRAY | Buy | VIEWRAY INC | $643,000 | +38.9% | 100,000 | +100.0% | 0.02% | +20.0% |
| GERN | New | GERON CORPput | $600,000 | – | 600,000 | +100.0% | 0.02% | – |
| TRHC | New | TABULA RASA HEALTHCARE INC | $569,000 | – | 14,663 | +100.0% | 0.02% | – |
| VTL | New | VITAL THERAPIES INCput | $454,000 | – | 150,000 | +100.0% | 0.01% | – |
| ADVM | New | ADVERUM BIOTECHNOLOGIES INC | $469,000 | – | 80,845 | +100.0% | 0.01% | – |
| SGMO | New | SANGAMO THERAPEUTICS INC | $475,000 | – | 25,000 | +100.0% | 0.01% | – |
| REGN | New | REGENERON PHARMACEUTICALScall | $335,000 | – | 50,000 | +100.0% | 0.01% | – |
| VCEL | New | VERICEL CORP | $271,000 | – | 27,211 | +100.0% | 0.01% | – |
| SGYPQ | New | SYNERGY PHARMACEUTICALS DEL | $183,000 | – | 100,000 | +100.0% | 0.01% | – |
| PTLA | New | PORTOLA PHARMACEUTICALS INCput | $158,000 | – | 100,000 | +100.0% | 0.00% | – |
| ONCS | New | ONCOSEC MED INC | $94,000 | – | 50,000 | +100.0% | 0.00% | – |
| BIIB | New | BIOGEN INCcall | $11,000 | – | 50,000 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
About Perceptive Advisors
Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.
The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.
One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.
Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES SHARES | 42 | Q3 2023 | 15.7% |
| AMICUS THERAPEUTICS SHARES | 39 | Q3 2023 | 14.0% |
| ALDEYRA THERAPEUTICS SHARES | 35 | Q3 2023 | 3.3% |
| QUOTIENT TECHNOLOGY INC | 34 | Q3 2022 | 2.7% |
| GLOBAL BLOOD THERAPEUTICS SHARES | 29 | Q3 2022 | 9.3% |
| ADMA BIOLOGICS SHARES | 29 | Q3 2023 | 1.4% |
| RETROPHIN SHARES | 28 | Q3 2020 | 5.5% |
| DBV TECHNOLOGIES SA-SPON ADR | 28 | Q3 2021 | 1.8% |
| VBI VACCINES SHARES | 27 | Q1 2023 | 2.8% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
View Perceptive Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHEMBIO DIAGNOSTICS, INC.Sold out | May 04, 2023 | 0 | 0.0% |
| VBI Vaccines Inc/BC | April 07, 2023 | 43,509,553 | 16.7% |
| Landos Biopharma, Inc. | March 30, 2023 | 14,869,915 | 47.7% |
| REATA PHARMACEUTICALS INC | March 07, 2023 | 2,083,799 | 6.5% |
| AGILE THERAPEUTICS INCSold out | February 14, 2023 | 0 | 0.0% |
| ALBIREO PHARMA, INC. | February 14, 2023 | 1,757,160 | 8.5% |
| BELLUS Health Inc. | February 14, 2023 | 8,891,027 | 7.1% |
| CinCor Pharma, Inc. | February 14, 2023 | 2,576,325 | 5.9% |
| Coherus BioSciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CONCERT PHARMACEUTICALS, INC. | February 14, 2023 | 1,800,000 | 3.6% |
View Perceptive Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-04-17 |
| 4 | 2024-04-15 |
| SC 13G/A | 2024-04-15 |
| SC 13G | 2024-04-15 |
| SC 13D/A | 2024-04-10 |
| 4 | 2024-04-08 |
| 4 | 2024-04-03 |
| SC 13D/A | 2024-04-03 |
| SC 13D | 2024-03-20 |
View Perceptive Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.